Interim analysis of ELEANOR (n=200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib

被引：0

作者：

Bartsch, R. ^{[1
]}

Harbeck, N. ^{[2
,3
]}

Wrobel, D. ^{[4
]}

Zaiss, M. ^{[5
]}

Terhaag, J. ^{[6
]}

Guth, D. ^{[7
]}

Distelrath, A. ^{[8
]}

Wuerstlein, R. ^{[2
,3
]}

Zahn, M. -O. ^{[9
]}

Lueftner, D. ^{[10
,11
]}

Schwitter, M. ^{[12
]}

Balic, M. ^{[13
]}

Jackisch, C. ^{[14
]}

Mueller, V. ^{[15
]}

Rinnerthaler, G. ^{[16
]}

Schmidt, M. ^{[17
]}

Zaman, K. ^{[18
]}

Schinkoethe, T. ^{[19
]}

Gorray, M. ^{[20
]}

Breitenstein, U. ^{[21
]}

机构：

[1] Med Univ Vienna, Div Oncol, Dept Med 1, Vienna, Austria

[2] LMU Univ Hosp, Dept OB GYN, Breast Ctr, Munich, Germany

[3] LMU Univ Hosp, CCC Munich, Munich, Germany

[4] Sozialstiftung Bamberg Klinikum Bruderwald, Bamberg, Germany

[5] Oncol Practice, Freiburg, Germany

[6] Rottal Inn Clin, Eggenfelden, Germany

[7] Gyneco Oncol Practice Dr Guth, Plauen, Germany

[8] Praxisgemeinschaft Onkol & Urol, Wilhelmshaven, Germany

[9] MVZ Onkol Kooperat Harz, Goslar, Germany

[10] Immanuel Hosp Mark Schweiz, Brandenburg, Germany

[11] Med Univ Brandenburg Theodor Fontane, Brandenburg, Germany

[12] Kantonsspital Graubunden, Chur, Switzerland

[13] Med Univ Graz, Dept Internal Med, Div Oncol, Graz, Austria

[14] Sana Klinikum Offenbach, Dept Gynecol & Obstet, Offenbach, Germany

[15] Univ Hosp Hamburg Eppendorf, Dept Gynecol & Obstet, Hamburg, Germany

[16] Paracelsus Med Univ Salzburg, Dept Internal Med 3, Salzburg, Austria

[17] Univ Hosp Mainz, Dept Gynecol, Mainz, Germany

[18] Lausanne Univ Hosp CHUV, Breast Ctr, Lausanne, Switzerland

[19] CANKADO Serv GmbH, Kirchheim, Germany

[20] Pierre Fabre Pharma GmbH, Freiburg, Germany

[21] Brust Zentrum Zurich, Div Oncol, Zurich, Switzerland

来源：

BREAST | 2023年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P014

引用

下载

页码：S20 / S21

页数：2

共 42 条

[41] Identification of patients (pts) at high risk for early death with advanced or metastatic breast cancer (MBC), not receiving salvage treatment after 1st-line (1stL) therapy with trastuzumab (T) - Results of a prospective national non-interventional study (NIS) in Germany
Jackisch, C.
Schoenegg, W.
Reichert, D.
Welslau, M.
Selbach, J.
Harich, H-D
Tesch, H.
Keitel, S.
Hinke, A.
CANCER RESEARCH, 2016, 76
[42] Germline BRCA1/2 and other predisposition genes in high-risk early-stage HR+/HER2-breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study
Loibl, Sibylle
Hauke, Jan
Gelmon, Karen
Marme, Frederik
Ernst, Corinna
Martin, Miguel
Untch, Michael
Bonnefoi, Herve
Knudsen, Erik
Im, Seock-Ah
DeMichele, Angela
Van't Veer, Laura
Kim, Sung-Bae
Bear, Harry
McCarthy, Nicole
Turner, Nicholas
Witkiewicz, Agnieszka
Rojo, Federico
CANCER RESEARCH, 2022, 82 (04)

← 1 2 3 4 5 →